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The production of native-like recombinant versions of
the HIV-1 envelope glycoprotein (Env) trimer requires
overcoming the natural flexibility and instability of the
complex. The engineered BG505 SOSIP.664 trimer
mimics the structure and antigenicity of native Env.
Here, we describe how the introduction of new disul-
fide bonds between the glycoprotein (gp)120 and
gp41 subunits of SOSIP trimers of the BG505 and
other genotypes improves their stability and antige-
nicity, reduces their conformational flexibility, and
helps maintain them in the unliganded conformation.
The resulting next-generation SOSIP.v5 trimers
induce strong autologous tier-2 neutralizing antibody
(NAb) responses in rabbits. In addition, the BG505
SOSIP.v6 trimers inducedweakheterologousNAb re-
sponses against a subset of tier-2 viruses that were
notelicitedby theprototypeBG505SOSIP.664.These
stabilization methods can be applied to trimers from
multiple genotypes as components of multivalent
vaccines aimed at inducing broadly NAbs (bNAbs).
INTRODUCTION
Despite many attempts, no experimental vaccine has induced
strongly protective immunity against HIV-1 infection. One
approach to this problem is the generation of an envelope glyco-
protein (Env)-based vaccine that induces broadly neutralizingCell R
This is an open access article under the CC BY-Nantibodies (bNAbs) (van Gils and Sanders, 2013). A major
obstacle to creating such a vaccine is the instability of the Env
trimer, which for many years hindered the generation of recom-
binant, soluble proteins that adequately mimicked the functional
Env trimer on virions.
We have described a soluble, recombinant Env trimer, BG505
SOSIP.664, that is stabilized by a disulfide bond between glyco-
protein (gp)120 and gp41 and an Ile-to-Pro substitution at posi-
tion 559 in gp41 (Binley et al., 2000; Sanders et al., 2002, 2013).
Several BG505 trimer structures, determined byX-ray crystallog-
raphy and cryoelectron microscopy (cryo-EM), have provided
new insights into the architecture and function of HIV-1 Env (Gar-
ces et al., 2015; Julien et al., 2013a; Kwon et al., 2015; Lee et al.,
2016; Lyumkis et al., 2013; Pancera et al., 2014; Sanders and
Moore, 2014; Scharf et al., 2015; Stewart-Jones et al., 2016).
Negative-stain electron microscopy (EM) and cryo-EM studies
show that it closely resembles the native, membrane-associated
trimer at the structural level (Lee et al., 2016; Lyumkis et al., 2013;
Sanders et al., 2013). TheBG505SOSIP.664 trimer, and others of
the same design based on different genotypes, displays the epi-
topes for most bNAbs and few non-NAbs (Derking et al., 2015;
Huang et al., 2014; Julien et al., 2013b; Sanders et al., 2013). In
immunogenicity studies in rabbits, the BG505, AMC008, B41,
CZA97, and DU422 SOSIP.664 trimers induced NAbs against
the corresponding autologous viruses (Cheng et al., 2015; Klasse
et al., 2016; Sanders et al., 2015; de Taeye et al., 2015).
Although SOSIP.664 trimers are stable enough to produce and
purify, we hypothesized that their performance as immunogens
could be improved by reducing their conformational flexibility
and the consequent exposure of immunodominant, potentially
distractive non-NAb epitopes (de Taeye et al., 2015).eports 20, 1805–1817, August 22, 2017 ª 2017 The Authors. 1805
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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The increasingly high-resolution structures of SOSIP trimers
greatly facilitate the design of stabilization strategies. BG505
SOSIP.664 trimers have already been further stabilizedby adding
an intra-gp120disulfidebond linking residues201and433,which
fixes the bridging sheet in its ground state and thereby reduces
the exposure of non-NAb epitopes (Guenaga et al., 2015; Kwon
et al., 2015). Combining two different substitutions in the gp120
subunit, E64K or H66R plus A316W, defined as SOSIP.v4, in-
creases the stability of trimers of various genotypes, reduces
the exposure of non-NAb CD4i and V3 epitopes (i.e., 17b, 19b,
and 14e), and decreases the induction of V3-directed non-
NAbs in immunized rabbits (de Taeye et al., 2015). Forming
a complex with the quaternary-structure-dependent bNAb,
PGT145, can also improve trimer stability (Cheng et al., 2015).
Moreover, by comparing the BG505 sequence with other se-
quences that form stable trimers poorly, several substitutions
were identified that increase the stability of JR-FL and 16055
SOSIP.664 trimers (Guenaga et al., 2015). Steichen et al. (2016)
usedmammalian cell surface display to design stabilized trimers
that showed an improvement in trimer expression and reduction
of V3 exposure. A considerable improvement in yield was
achievedbycomputationally redesigning theN-terminal residues
of heptad region 1 (HR1) of Env SOSIP trimers (Kong et al., 2016).
Finally, we have also introduced a disulfide bond between gp120
residue-49 of one protomer and gp41 residue-555 of a second
protomer to increase thermostability of the trimer. Strong prece-
dents underpin this approach as disulfide bonds play a well-
established role in protein stability (Camacho and Thirumalai,
1995; Creighton, 1988). For example, disulfide bonds can be up
to 17-fold more abundant in proteins from thermophilic archea
and bacteria, compared to mesophiles, and the number of disul-
fides correlates with their maximum growth temperature (Liszka
et al., 2012). Furthermore, disulfide bonds have been used to sta-
bilize the immunogens from respiratory syncytial virus (RSV) and
influenza virus (Lee et al., 2016; McLellan et al., 2013).
Here, we describe the structure-guided introduction of addi-
tional disulfide bonds between gp120 and gp41 that further sta-Figure 1. Design, Antigenicity, Structure, and Conformational Dynam
between gp120 and gp41
(A) Linear schematic of the BG505 SOSIP.664, SOSIP.v4, SOSIP.v5, SOSIP.v
SOSIP.664 construct are indicated in red (Sanders et al., 2013). The E64K and A
(de Taeye et al., 2015). The engineered disulfide bonds in SOSIP.v5 are shown in
disulfide bond between H72C and H564C and the SOSIP.v5.2 has a disulfide b
described by Kwon et al. (2015), was introduced into the SOSIP.v5.2 background.
The resulting constructs are designated SOSIP.v5.2 I201C-A433C and SOSIP.v6
(B) SPR analysis of the binding of bNAbs PG16, PGT145, PGT151, and 35O22 to
(±prior addition of CD4-IgG2) (lower panel), to the indicated BG505 trimer varian
(C) Crystal structure of the quaternary complex of BG505 SOSIP.664 H72C-H56
NIH45-46 scFv (deep blue). The three different antibody Fab or scFv fragments
spheres. One of the three protomers is highlighted for clarity, and the gp41 central
with a rectangle.
(D) Detail of the interaction between gp41 HR1 and gp120. A 2Fo-Fc composite
electron density (greenmesh) for gp41 HR1N residues 547–569 (dotted lines), impl
in a ground-state prefusion conformation. The figure was rendered using PyMOL
(E) Differences in hydrogen/deuterium (H/D) exchange rates between the unliga
between the two states is the difference obtained by subtracting the deuterons
CD4-bound forms. While positive values indicate that the residues were destabili
difference in H/D exchange as a sum of all time points is plotted for each observa
the summation process. The same set of peptides was used for each trimer conbilize the resulting SOSIP.v5 trimers in their unliganded, closed
state. Furthermore, we have combined these intra-protomer
bonds with recently described inter-protomer bonds to create
hyperstable SOSIP.v6 trimers. When BG505 SOSIP.v6 trimers
were tested as immunogens in rabbits, they induced strong
autologous responses, as well as weak, but consistent, NAbs
against a subset of heterologous tier-2 viruses.
RESULTS
Addition of a Second Disulfide Bond between gp120 and
gp41
To reduce the flexibility and increase the stability of BG505
SOSIP.664 trimers, we designed, screened, and produced vari-
ants containing an additional engineered intra-protomer disul-
fide bond; i.e., between the gp120 and gp41 subunits. Since
the disulfide bond between residue 501 of gp120 and residue
605 of gp41 (i.e., the SOS bond), used to create SOSIP trimers,
is located near the base of the trimer (Binley et al., 2000; Garces
et al., 2015; Pancera et al., 2014), we sought more central loca-
tions for a second intra-protomer bond. Initially, new disulfide
bonds were evaluated in the absence of the SOS bond, and a
few promising candidates were subsequently chosen to make
double disulfide-bond variants (Figures S1 and S2). Based on
favorable biochemical and antigenic properties, we selected
two such variants, designated SOSIP.664 H72C-H564C and
SOSIP.664 A73C-A561C, for further analyses (Figures S1 and
S2). To provide additional stability, we also introduced two point
substitutions: A316W to improve hydrophobic packing of V3
residues and prevent sporadic, unwanted V3 exposure from
its hidden location below V1V2 and E64K to impede the occa-
sional spontaneous and reversible sampling of the CD4-bound
conformation (Figure 1A; de Taeye et al., 2015). SOSIP.664 tri-
mers containing the E64K and A316W substitutions and either
an H72C-H564C or A73C-A561C disulfide bond are referred to
as SOSIP.v5.1 or SOSIP.v5.2 variants, respectively (Figure 1A;
see also Table S1).ics of BG505 SOSIP.v5 Trimers Containing Novel Disulfide Bonds
5.2 I201C-A433C, and SOSIP.v6 constructs. Modifications that create the
316W substitutions added to make the SOSIP.v4 construct are colored blue
purple. There are two variants of the SOSIP.v5 construct: the SOSIP.v5.1 has a
ond between A73C and A561C. The I201C-A433C disulfide bond, previously
The E49C-L555C disulfide bondwas introduced into the SOSIP.v5.2 construct.
, respectively.
quaternary epitopes (upper panel), and of CD4-IgG2 and non-NAb 17b CD4i
ts.
4C trimer (cyan) in complex with PGT122 Fab (pink), 35O22 Fab (orange), and
are represented as colored surfaces, and the trimer N-linked glycans as cyan
HR1 helix location proximal to the engineered H72C-H564C disulfide ismarked
omit map contoured at 1.0s around gp41 HR1 (blue mesh) reveals ordered
ying that the H72C-H564C disulfide bond helps stabilize this region of the trimer
.
nded and CD4-bound forms of the indicated SOSIP variants. The difference
exchanged in the unliganded condition from the deuterons exchanged in the
zed in the presence of 2D-sCD4, negative values indicate stabilization. The net
ble peptide. Only differences that were outside the error range were included in
struct. The individual exchange plots are shown in Data S1A.
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Biochemical and Biophysical Properties of Stabilized
BG505 SOSIP.v5 Trimers
The two variants of BG505 SOSIP.v5 trimers were expressed
in 293F cells and purified via PGT145-affinity chromatography,
as previously described (de Taeye et al., 2015). Non-reducing
SDS-PAGE analysis showed that the SOSIP.v5 proteins
migrated more slowly than their SOSIP.664 counterparts (Fig-
ures S3A and S3B), consistent with a decrease in SDS uptake
when a protein becomes more compact. We used tandem
mass spectrometry (MS/MS) to confirm that, in addition to the
ten canonical disulfide bonds and the SOS bond, the new
bond was also formed in both SOSIP.v5 variants (Table S5).
PGT145-purified, native-like BG505 SOSIP.664 trimers have
a more open configuration on average compared to those puri-
fied by 2G12 columns, typically 30% versus >95% closed
(de Taeye et al., 2015). The addition of the H72C-H564C or
A73C-A561C disulfides further increases to 85% closed for
SOSIP.v5.1 and 90% for SOSIP.v5.2 trimers (Table 1 and Fig-
ure S3C). Dynamic light scattering (DLS) studies support the
conclusion that both SOSIP.v5 trimers are more compact (see
Table S2 and Figure S3D for these and other biophysical ana-
lyses, including small angle X-ray scattering [SAXS]).
We then assessed BG505 trimer thermostability. The introduc-
tion of either disulfide bond in the SOSIP.v4.1 context again
increased trimer thermostability with Tm values of 75.0
C and
75.3C for SOSIP.v5.1 and SOSIP.v5.2, respectively, represent-
ing increases of 4.3C and 4.6C over SOSIP.v4.1 and 7.4C and
7.7C over SOSIP.664 (Table 1; Figure S3E).
The glycosylation profiles of the SOSIP.664 H72C-H564C,
SOSIP.664 A73C-A561C, and both SOSIP.v5 trimers were all
similar to those of SOSIP.664 and SOSIP.v4.1, with oligoman-
nose glycoforms dominating (61%–64%) and, in particular,
Man8GlcNAc2 and Man9GlcNAc2 glycans (Table 1; Figure S3F).
The high density of unprocessed oligomannose glycans on
gp120 is a hallmark of native-like Env trimers (Pritchard et al.,
2015a, 2015b).
Antigenicity of Stabilized BG505 SOSIP.v5 Trimers
We used a panel of bNAbs to assess the antigenicity of stabilized
BG505 trimer variants by ELISA. All of the tested bNAbs bound
comparably to the SOSIP.664, SOSIP.v4, and SOSIP.v5 trimers,
implying that the changes did not compromise antigenicity
(Table 2; Data S1A). Surface plasmon resonance (SPR) studies
confirmed that the quaternary-structure-dependent epitopes at
the trimer apex (PG16 and PGT145) and at the gp120/gp41 inter-
face (35O22 and PGT151) were fully preserved on both versions
of SOSIP.v5 trimers (Figure 1B). SPR analysis showed that the
association of CD4-IgG2 was similar between SOSIP.664 and
SOSIP.v5, but the dissociation from both SOSIP.v5 variants
was markedly faster (Figure 1B), consistent with previous mea-
surements with SOSIP.v4 trimers (de Taeye et al., 2015). These
data are also consistent with a report in which stabilization of
BG505 SOSIP.664 with an intra-gp120 disulfide bond (DS-
SOSIP.664) was shown to increase soluble CD4 (sCD4) dissoci-
ation (Kwon et al., 2015).
BG505 SOSIP.664 trimersminimally, but detectably, bind 17b,
a non-NAb against a CD4-inducible (CD4i) epitope, by ELISA
(Sanders et al., 2013). Under the same conditions, neither1808 Cell Reports 20, 1805–1817, August 22, 2017SOSIP.v5 trimer bound detectably to 17b when CD4-immuno-
globulin G (IgG2) was absent, and the extent of CD4i-epitope
induction by CD4-IgG2 was less than with SOSIP.664 and
SOSIP.v4.1 in ELISA (Table 2; Data S1B). SPR analysis
confirmed and extended these results (Figure 1B). Moreover,
non-NAb b6 that targets the CD4 binding site (CD4bs) bound
less well to the SOSIP.v5 trimers than to SOSIP.664 and
SOSIP.v4.1 (Table 2; Data S1B). Some of the reduction in non-
NAb epitope exposure in SOSIP.v5 is attributable to the
A316W substitution that is present in SOSIP.v4 trimers (de Taeye
et al., 2015). However, the new disulfide bonds in the SOSIP.v5
trimers confer additional benefits (Table 2; Data S1B).
Taken together, the antigenicity studies show that the
SOSIP.v5 trimers preserve the desired bNAb reactivity profiles
of their SOSIP.664 and SOSIP.v4.1 precursors.
X-Ray Structure of a Stabilized BG505 SOSIP Trimer
To assess the impact of an extra disulfide bond on the trimer
structure, we expressed the BG505 SOSIP.664 H72C-H564C
trimer in N-acetyl-glucosaminyltransferase I (GnTI)-deficient
HEK293S cells and purified it by 2G12-affinity chromatography
followed by size exclusion chromatography (SEC). Its crystal
structure was determined in complex with bNAbs PGT122
Fab, 35O22 Fab, and NIH45-46 scFv (Figure 1C). Although the
crystals only diffracted to 7 Å resolution, the availability of
higher-resolution structures of other BG505 SOSIP trimers al-
lowed a clear interpretation of the lower-resolution electron den-
sity maps, as exemplified by good refinement statistics (Table
S3). The overall architecture of the trimer is indeed preserved
upon addition of the 72C-564C inter-subunit disulfide bond
(Figure 1C). In addition, bNAbs against three distinct sites of
vulnerability (PGT122, N332; 35O22, gp41/gp120 interface;
and NIH45-46, CD4bs) interacted with their epitopes in a similar
manner to the SOSIP.664 trimer (Figure 1C). Residues 547–569
in the gp41 HR1N region near the 72C substitution in gp120
have defined electron density similar to that in higher-resolution
BG505 SOSIP.664 trimer structures (Garces et al., 2015; PDB:
5CEZ) filtered at the same resolution (Figure 1D), indicating
that this region is well ordered and native like. Thus, the added
H72C-H564C disulfide bond preserves the native-like trimer
structure.
Dynamics of BG505 SOSIP.v5 Trimers
We compared the SOSIP constructs by hydrogen-deuterium ex-
change (HD-X) to explore the impact of the new trimer-stabilizing
changes on protein dynamics and conformational flexibility. The
resulting exchange profiles for the BG505 SOSIP.664 A73C-
A561C, SOSIP.v5.1 and SOSIP.v5.2 trimers were overall consis-
tent with the SOSIP.664 precursor (Figure S4). Only a few minor
changes were observed, which are proximal to the newly intro-
duced disulfide linkages. We used the same method to compare
CD4-induced conformational changes. Addition of sCD4 to the
SOSIP.664 trimers resulted in less protection in the V2 and V3
loops, but more protection of the CD4bs, gp120 layers 1–3,
and gp41 HR1, in agreement with previous studies (Figures
1E and S4) (Guttman et al., 2014). The changes in the various sta-
bilized mutants were greatly diminished or completely abolished
(Figures 1E and S4). The SOSIP.v5.2 variant responded least to
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– SOSIP.664 2.0 98 35 67.6 – 18 23 64
H72C-H564C 2.0 98 70 71.9 4.3 21 20 63
A73C-A561C 2.0 98 70 72.5 4.9 ND ND ND
E64K A316W SOSIP.v4.1d 2.0 98 70 70.7 3.1 21 23 64
E64K A316W H72C-H564C SOSIP.v5.1 2.0 98 85 75.0 7.4 21 20 68
E64K A316W A73C-A561C SOSIP.v5.2 2.0 98 90 75.3 7.7 21 23 64
I201C-A433Ce DS-SOSIP 1.0 98 65 74.5 8.9 ND ND ND
E64K A316W A73C-A561C
I201C-A433C
1.5 98 85 80.7 13.1 23 19 61
E49C-L555Cf 0.2 ND ND 75.2 7.6 ND ND ND
E64K A316W A73C-A561C
E49C-L555C
SOSIP.v6 0.8 98 50 78.7/92.2g 11.2/24.6g 25 25 69
AMC008
– SOSIP.664 2.0 98 15 60.2 – 14 34 67
I535M L543N H66R A316W SOSIP.v4.2d 2.0 98 85 64.5 4.5 12 39 69
I535M L543N H66R A316W
H72C-H564C
SOSIP.v5.1 1.5 98 100 68.3 8.1 13 33 65
I535M L543N H66R A316W
A73C-A561C
SOSIP.v5.2 1.5 98 100 68.5 8.3 14 30 65
B41
– SOSIP.664 2.0 98 45 58.6 – 15 29 63
L543N E64K A316W SOSIP.v4.1d 2.0 98 55 60.7 2.1 14 32 64
L543N E64K A316W
H72C-H564C
SOSIP.v5.1 0,2 98 95 63.0 4.3 ND ND ND
L543N E64K A316W
A73C-A561C
SOSIP.v5.2 1.5 98 70 64.7 6.1 17 25 64
ZM197M
– SOSIP.664 0.3 95 15 62.2 – 22 26 70
V535M H66R T316W SOSIP.v4.2d 0.3 90 30 62.6 0.4 21 26 69
V535M H66R T316W
H72C-H564C
SOSIP.v5.1 1.0 98 100 69.5 7.3 ND ND ND
V535M H66R T316W
A73C-A561C
SOSIP.v5.2 1.0 98 100 69.2 7.0 ND ND ND
The yields of PGT145-purified trimers are listed, together with the percentages that have a native-like conformation and also in the completely closed
form, as determined by negative-stain EM. The 2D class averages were derived using trimers without a C-terminal tag and are shown in Figure S5C.
ND, not determined.
aAn overview of the modifications made to the stabilized trimer variants is shown in Table S1.
bThe Tm values for each construct were obtained by DSC using a two-state model (Figure S5D). The Tm values are based on two-state model fitting.
Tm values for His-tagged trimers (BG505) were consistently 0.9C –1.0C higher than the values for the same trimers without a tag. Tm values
obtained with D7324-tagged trimers (AMC008, B41, and ZM197M) were up to 0.3C higher than those without a tag.
cPercentages of Man8, Man9, and total oligomannose glycans are given for each trimer (Figure S5E). The percentage of Man8GlcNAc2 and
Man9GlcNAc2 glycans, as well as the total percentage of oligomannose glycans are provided for each His/D7324-tagged trimer (Figure S5E).
dNS-EM and glycan composition data for SOSIP v4.1 and SOSIP v4.2 trimers were previously reported in de Taeye et al. (2015).
eData for this trimer variant were previously described in Kwon et al. (2015) and Guenaga et al. (2015). Experiments were performed with newly purified
trimers.
fSOSIP.664 trimer variant was described in Garces et al. (2015). Experiments were performed with newly purified trimers.
gThe two values represent the peaks of the two independent unfolding events observed by DSC (see Figure S3E for the raw data).
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Broadly Neutralizing Antibodies Non-neutralizing Antibodies
V1V2 Apex V3-Glycan OD Glycan CD4bs gp120-gp41 Interface CD4i V3 CD4bs CD4bs
PG9 PG16 PGT145 PGT121 2G12 VRC01 PGT151 35022 3BC315 17b 17b+sCD4 14e 19b B6 CD4 IgG2
BG505
– SOSIP.664 0.079 0.054 0.020 0.044 0.014 0.022 0.016 0.026 0.130 0.304 0.077 0.039 0.013 0.143 0.020
H72C-H564C 90 98 76 88 129 118 87 73 89 0 56 72 88 55 80
A73C-A561C 95 158 84 115 119 105 136 93 111 0 43 71 83 59 61
E64K A316W SOSIP.v4.1b 91 93 77 101 104 113 107 71 106 0 15 2 0 13 54
E64K A316W H72C-H564C SOSIP.v5.1 69 81 94 72 103 106 118 77 95 0 8 2 4 9 35
E64K A316W A73C-A561C SOSIP.v5.2 77 94 86 79 122 116 131 75 93 0 8 2 5 7 55
E64K A316W A73C-A561C
I201C-A433C
76 95 231 88 85 87 135 130 102 0 0 2 9 10 61
E64K A316W A73C-A561C
E49C-L555C
SOSIP.v6 112 103 135 58 123 78 130 85 99 0 9 2 6 5 68
AMC008
– SOSIP.664 ND 1.761 1.300 0.026 0.010 0.061 0.162 0.832 0.050 0.13 0.001 0.002 ND 0.017 0.534
I535M L543N H66R A316W SOSIP.v4.2a ND 62 125 114 95 102 115 162 116 0 1 6 ND 30 103
I535M L543N H66R A316W
H72C-H564C
SOSIP.v5.1 ND 128 134 127 69 102 118 171 107 0 1 12 ND 34 63
I535M L543N H66R A316W
A73C-A561C
SOSIP.v5.2 ND 127 130 119 40 118 185 231 95 0 0 10 ND 23 96
B41
– SOSIP.664 0.077 0.094 0.151 0.053 0.043 0.126 0.152 1.665 0.024 0.839 0.001 0.007 0.003 0.017 0.029
L543N E64K A316W SOSIP.v4.1a 97 104 92 108 102 126 121 115 58 0 1 8 14 20 21
L543N E64K A316W
H72C-H564C
SOSIP.v5.1 127 73 59 104 70 125 232 135 44 0 2 1 18 34 9
L543N E64K A316W
A73C-A561C
SOSIP.v5.2 113 418 86 116 125 116 221 159 84 0 5 28 16 23 23
ZM197M
– SOSIP.664 0.263 0.487 2.310 0.192 0.126 0.034 0.142 0.013 0.022 0.10 0.055 0.064 0.637 0.295 0.138
V535M H66R T316W SOSIP.v4.2a 73 93 113 88 95 108 95 85 28 0 42 14 55 59 92
V535M H66R T316W
H72C-H564C
SOSIP.v5.1 16 91 352 84 96 125 234 92 28 0 3 12 17 9 13
V535M H66R T316W
A73C-A561C
SOSIP.v5.2 30 121 342 87 102 116 267 425 45 0 5 19 36 10 26
Binding of bNAbs and non-NAbs was determined using a Ni-NTA (BG505) or a D7324- (AMC008, B41, and ZM197M) capture ELISA. Half-maximal binding concentrations (half maximal effective
concentration [EC50], in mg/mL) are shown for SOSIP.664 trimers (underlined). Antibody binding to the various stabilized trimers is expressed as percentage of the binding to SOSIP.664 (EC50 is
defined as 100%). The values are representative of at least two independent experiments. The ELISA curves from one representative experiment are shown in Data 1B–1E. ND, not determined.
aAn overview of the modifications made to the stabilized trimer variants is shown in Table S1.






































sCD4, in that the CD4-induced exposure of V2 and V3 was now
entirely abrogated (Figure S4). Thus, the extra inter-subunit di-
sulfide bond and the E64K and A316W substitutions are syner-
gistic in preventing the opening of the apex of the SOSIP.v5.2 tri-
mers when sCD4 is present. The data strongly suggest that the
BG505 SOSIP.v5.2 trimers are effectively trapped in the closed,
ground state.
Stabilizing SOSIP Trimers from Clades B and C
To assess the generality of the stabilization method, we intro-
duced the H72C-H564C or A73C-A561C disulfide bonds into
B41 (clade B) SOSIP.v4.1, AMC008 (clade B), and ZM197M
(clade C) SOSIP.v4.2 constructs (Julien et al., 2015; Pugach
et al., 2015; de Taeye et al., 2015). The resulting variants were
purified and analyzed by SDS-PAGE and blue native (BN)-
PAGE analysis. While AMC008 SOSIP.v5 and B41 SOSIP.v5
yielded similar trimer amounts to comparably produced
SOSIP.664 and SOSIP.v4 counterparts, the yields for ZM197M
were considerably improved (1.0 mg/L for SOSIP.v5.1 and v5.2
versus 0.3 mg/L for SOSIP.664 and SOSIP.v4) (Table 1). All
of the variously purified SOSIP.v5 trimers were cleaved effi-
ciently (Figures S5A and S5B) and migrated more slowly on
non-reducing SDS-PAGE gels (Figure S5A). Negative-stain EM
confirmed that the PGT145-purified SOSIP.v5 trimers were
again invariably native like and alsomore likely to be in the closed
conformation (Table 1; Figure S5C). As for BG505, oligomannose
glycoforms dominated (63%–70%, in particular Man8GlcNAc2
and Man9GlcNAc2, Table 1; Figure S5E). The additional disulfide
bond improved the thermostability of each trimer construct. For
AMC008, the Tm increased from 60.2
C (SOSIP.664) to 68.3C–
68.5C (SOSIP.v5.1 and v5.2; Table 1; Figure S5D). Increases in
Tm of between 4
C and 7C compared to SOSIP.664 were also
observed for the various B41 and ZM197M SOSIP.v5.1 and
SOSIP.v5.2 trimers (Table 1; Figure S5D). Overall, we conclude
that introducing a second inter-subunit disulfide bond confers
additional stability on SOSIP.v5 trimers of four different isolates
from three different clades.
Antigenic Properties of B41, AMC008, and ZM197M
SOSIP.v5 Trimers
In general, the antigenicity properties of the SOSIP.v5.1 and v5.2
trimers of all three genotypes were again comparable to the cor-
responding SOSIP.v4 and/or SOSIP.664 trimers, bNAb binding
was retained, while non-NAb reactivity with V3 and CD4i epi-
topes was reduced (Table 2; Data S1C–S1E). CD4-IgG2 binding
to B41 and ZM197M SOSIP.v5 variants was reduced compared
to SOSIP.v4 (Table 2). An unexpected observation was that
introduction of an additional disulfide bond into the ZM197M
SOSIP.v5 construct improved binding of the quaternary-struc-
ture-dependent bNAb PGT145 and PGT151, compared to
SOSIP.664 and SOSIP.v4 trimers (Table 2; Data S1C). We
noticed that in contrast to the quaternary-specific PGT145
bNAb, the quaternary preferring PG9 showed a slightly
decreased binding for ZM197M SOSIP.v5 compared to
SOSIP.664 (Table 2; Data S1C). The introduction of an additional
disulfide bond also had a noticeable effect for B41, for which
PGT151 bindingwas negligible for SOSIP.664 trimers, but strong
for both SOSIP.v5 versions (Table 2; Data S1D). We canconclude that SOSIP.v5 exhibits a similar or somewhat better
antigenic profile compared to SOSIP.664 and SOSIP.v4.1.
Comparison and Combination with Other Trimer
Stabilization Approaches
Two other SOSIP trimer stabilization strategies are outlined in
Figure 1A. First, introducing a disulfide bond between residues
201 and 433 (substitutions I201C and A433C) in the gp120
bridging sheet has been reported to increase the thermostability
and reduce the conformational flexibility of these BG505 trimers
(Kwon et al., 2015). Second, a disulfide bond between gp120 and
gp41 of different protomers (substitutions E49C and L555C) also
makes BG505 trimers more thermostable (Garces et al., 2015).
BG505 SOSIP trimer variants containing either of these disulfide
bonds have a reduced exposure of CD4i non-NAb epitopes (Gar-
ces et al., 2015; Kwon et al., 2015).
We introduced the above disulfide bonds into BG505
SOSIP.664 or SOSIP.v5.2 constructs and determined the yields,
antigenic profiles, and thermal stability of the resulting trimers.
The SOSIP.v6 construct contains the E49C-L555C substitutions
on the SOSIP.v5.2 background, while the ‘‘SOSIP.v5.2 I201C-
A433C’’ construct includes the 201C-433C disulfide bond in the
SOSIP.v5.2 background (Figure 1A). The yields of PGT145-puri-
fied SOSIP.v5.2 I201C-A433C and SOSIP.v6 trimers (1.5 and
0.8 mg/L, respectively) were lower than for SOSIP.664 and
SOSIP.v5.2 (2.0mg/L) (Table1).Non-reducingSDS-PAGEanal-
ysis showed that SOSIP.v6 proteinsmigrated as a trimer, which is
consistent with the formation of inter-protomer disulfide bonds
(Table S3A). However, two subpopulations were visible on the
gels. Based on a comparison with the migration patterns of
various control proteins, we propose that the slower migrating
variant,60% of the total, contains all three engineered disulfide
bonds (501C-605C, 73C-561C, and 49C-555C), while the faster
migrating species lacks the 73C-561C bond whose formation
maybe restricted by thepresenceof the 49C-555Cbond in a sub-
population of trimers (Figure S3A).
The antigenic profile of these more stable trimers, SOSIP.v5.2
I201C-A433C and SOSIP.v6, are very similar to their less stable
counterparts. The quaternary antibodies PGT151 and PGT145
bound slightly more strongly to the BG505 SOSIP.v5.2 I201C-
A433C and SOSIP.v6 trimers than to their precursors, while the
binding of non-NAbs to V3 and CD4i epitopes remained very
low (Table 2; Data S1B). Both new trimers resembled their pre-
cursors in containing mostly oligomannose glycoforms (Table 1;
Figure S3F).
The new disulfide bonds further increased BG505 trimer ther-
mostability. Adding the 201C-433C bond to the SOSIP.v5.2
construct increased the Tm from 75.3
C to 80.7C. The SOSIP.v6
trimer was particularly thermostable, the Tm of the majority sub-
population was 92.2C, while a smaller unfolding event was
detected at 78.8C, which we propose reflects theminority of tri-
mers in which the 73C-561C linkage is not formed (Table 1;
Figure S3E).
Immunogenicity of Stabilized BG505 SOSIP Trimers in
Rabbits
We compared the immunogenicity of various prototypic and
stabilized BG505 SOSIP trimers in rabbits using a previouslyCell Reports 20, 1805–1817, August 22, 2017 1811
described protocol with 22 mg of trimer per dose and measuring
the antibody responses 2 weeks after the third immunization
(Figure 2A) (Sanders et al., 2015; de Taeye et al., 2015).
All the BG505 trimer-immunized animals had high and compa-
rable titers of binding antibodies to the corresponding trimers, as
measured in ELISA (Figure 2C). The sera from the SOSIP.664
trimer recipients consistently neutralized the autologous tier-2
BG505.T332N virus, which is consistent with our earlier reports
(Figure 2D) (Sanders et al., 2015; de Taeye et al., 2015). The cor-
responding gp120 monomer was almost entirely ineffective in
this regard, with only one of five animals responding weakly (Fig-
ure 2D). The inferiority of BG505 gp120 at inducing autologous
BG505.T332N NAbs was consistent with a previous report,
although the difference between the gp120 recipients and the
trimer-immunized animals was much more pronounced in the
current experiment (Sanders et al., 2015; Figure 2D). The autolo-
gous NAb responses elicited by the different trimers were
generally comparable (median half maximal inhibitory concen-
tration [IC50]; SOSIP.664, 4432; SOSIP.v4.1, 4503; SOSIP.v5.1 +
SOSIP.v5.2 pooled, 3457; and SOSIP.v6, 7,798), except for the
SOSIP.v5.2 I201C-A433C hyperstabilized trimer (median IC50,
226; p = 0.0159 compared to SOSIP.664) (Figure 2D). Thus,
with the possible exception of the I201C-A433C change to the
SOSIP.v5.2 construct, the modifications used to create new,
more stable trimers do not impair the induction of the autologous
BG505.T332N NAb response.
One of the goals of trimer stabilization projects is to reduce the
antigenicity and immunogenicity of epitopes for non-NAbs and
tier-1 NAbs, the latter being dominated by V3-directed anti-
bodies, and thereby focus the immune response on more pro-
ductive targets (Kwon et al., 2015; de Taeye et al., 2015).
Compared to the BG505 SOSIP.664 trimers and, more so,
the gp120 monomers, NAb titers against the tier-1A SF162
virus were reduced by 3-fold for the combined SOSIP.v5.1
andSOSIP.v5.2 groups (p= 0.0175 versusSOSIP.664; not statis-
tically significant versus SOSIP.v4.1) and were also lower
for SOSIP.v5.2 201C-433C (not statistically significant versus
SOSIP.664). In contrast, the SF162NAb titers, aswell as V3 bind-
ing antibody titers (data not shown), were almost 7-fold higher
in the SOSIP.v6 group compared to the combined SOSIP.664,
SOSIP.v4.1, and SOSIP.v5 groups (p = 0.0031; Figure 2E).
Sera from the various BG505 trimer-immunized rabbits were
generally weakly and sporadically active against a panel of
heterologous tier-2 viruses (Table S4A). While the clade A virus
92RW020, the clade B virus SHIV162P3, and the clade C
TV1.21 virus were poorly or not neutralized by SOSIP.664-,
SOSIP.v4.1-, or SOSIP.v5-immunized animals (median IC50
values for the combined SOSIP.664, SOSIP.v4.1, and SOSIP.v5
groups of 25, 20, and 28, respectively), they were more consis-
tently neutralized by sera from SOSIP.v6 recipients (IC50
values of 56, 45, and 97). The differences in the ability to neutralize
92RW020, SHIV162P3, and TV1.21 between the BG505
SOSIP.v6 recipient animals and the animals that were immunized
with earlier BG505 SOSIP versions were statistically significant
(p = 0.0071, p = 0.0021, and p = 0.0207 for the three viruses,
respectively). In contrast, prebleed sera did not neutralize the
autologous BG505.T332N pseudovirus, nor the heterologous
92RW020 or SHIV162P3 pseudoviruses (Table S4C). For each in-1812 Cell Reports 20, 1805–1817, August 22, 2017dividual rabbit, we analyzed the number of heterologous tier-2 vi-
ruses that were neutralized with IC50 values >40. Neutralization at
this titer levelwasonly sporadic for theSOSIP.664,SOSIP.v4.1, or
SOSIP.v5 groups; themajority of the serawere inactive against all
heterologous Tier-2 viruses. In contrast, sera from the SOSIP.v6
group neutralized one (one animal), two (one animal), three (one
animal), or four (twoanimals) of thesixteenviruses in the test panel
at a titer >40 (Figure 2I and Table S4A).When the SOSIP.v6 group
was compared with the SOSIP.664, SOSIP.v4.1, SOSIP.v5.1 +
SOSIP.v5.2, and SOSIP.v5.2 I201C-A433C groups, the number
of heterologous Tier-2 viruses neutralized with IC50 values >40
was significantly higher (n = 14 for SOSIP.v6 versus n = 0, 4, 4,
and 6 for SOSIP.664, SOSIP.v4.1, SOSIP.v5.1 + SOSIP.v5.2,
and SOSIP.v5.2 I201C-A433C, respectively; Kruskal-Wallis p <
0.001 in each case) (Figure 2I).
Immunogenicity of Stabilized ZM197MSOSIP Trimers in
Rabbits
In a similar study, we tested the ZM197M SOSIP.664,
SOSIP.v4.2, and SOSIP.v5.2 trimers in rabbits (Figures 2J–2O).
The autologous trimer binding antibody titers were again compa-
rable among the groups, but 2- to 5-fold lower than those
induced by BG505 trimers (Figure 2J). The autologous NAb
response to the ZM197M trimers, in general, was also markedly
weaker and less consistent than seen with their BG505 counter-
parts (cf. Figure 2J with Figure 2C and Figure 2K with Figure 2D).
The ZM197M SOSIP.v5.2 trimer was clearly the most immuno-
genic for the autologous NAb response (5/5 responders, with a
median IC50 of 114, compared to 3/10 responders for the com-
bined SOSIP.664 and SOSIP.v4.2 groups; p < 0.0001 by c2
test; Figure 2K). The three ZM197M trimers induced SF162
tier-1A NAb titers to comparable extents (Figure 2L).
As seen in the BG505 study, sera against the various ZM197M
trimers only sporadically neutralized heterologous tier-2 viruses
(Table S4A). Overall, the most frequent NAb responses to
92RW020, SHIV162P3, and TV1.21 were induced by the
ZM197M SOSIP.v5.2 variant (p = 0.007, non-significant and p =
0.0137 for 92RW020, SHIV162P3, and TV1.21, respectively
compared to SOSIP.664 and SOSIP.v4.2 combined; Figures
2N–2P). Three of the five SOSIP.v5.2 sera neutralized three
heterologous tier-2 viruses at a titer >40, while none of the
SOSIP.664 or SOSIP.v4.2 sera did so (Kruskal-Wallis p < 0.001;
Figure 2P). Assessed across the entire heterologous tier-2 panel,
the ZM197M SOSIP.v5.2 sera neutralized significantly more
viruses (IC50 values > 40) compared to the SOSIP.664 or
SOSIP.v4.2 groups (n = 9 versus 0 or 0, respectively, Fischer-
Freeman p < 0.0001; Figure 2P).
In conclusion, the hyperstable BG505 SOSIP.v6 trimers
induced significantly broader tier-2 NAb responses than the
SOSIP.664, SOSIP.v4, and SOSIP.v5 variants. For the
ZM197M genotype, the SOSIP.v5.2 construct was the most
broadly immunogenic for tier-2 NAbs compared to its SOSIP.664
and SOSIP.v4.2 counterparts.
Properties of the Autologous Tier-2 NAb Specificities
To investigate what epitopes were targeted by the autologous
BG505.T332N NAbs induced by, in particular, BG505 SOSIP.v6









Figure 2. Immunogenicity of BG505 and ZM197M SOSIP.v5
Trimers in Rabbits
(A) Schematic representation of immunization schedule.
(B) Color coding for the immunogens tested.
(C–I) Shows data for BG505-based immunogens.
(J –P) Shows data for ZM197M.
(C and J) Midpoint antibody binding titers (ED50) as measured by
D7324-capture ELISA for the trimer variants indicated on the x axis
at the bottom of the figure, and by the color-coding scheme outlined
in (B).
(D–H and J–O) Neutralization of HIV-1 viruses in the TZM-bl assay by
sera from animals immunized with BG505 or ZM197M trimer variants.
The plots show ID50 values, the serum dilution at which infectivity is
inhibited by 50%.
(D–H and K–O) Autologous viruses (D and K); SF162 heterologous
tier-1A (E and L); 92RW020 heterologous tier-2 virus (F and M);
SHIV162P3 heterologous tier-2 virus (G and N); and TV1.21 heterol-
ogous tier-2 virus (H and O).
(I and P) The cumulative numbers of heterologous viruses neutralized
with an ID50 >40 by the five sera from each group are shown. In the
particular case of the BG505 SOSIP.v5 group, where 15 animals were
analyzed (SOSIP.v5.1: five animals and SOSIP.v5.2: ten animals), the
number of heterologous hits was divided by three. Statistical tests
were performed using Mann-Whitney t test for (E)–(H) and Kruskal-
Wallis with Dunn’s post-test for (I) and (P). Note that Kruskal-Wallis
tests were performed on the ID50 values. The horizontal bars repre-
sent medians. Neutralization titers with SOSIP.v6 sera against
92RW020, SHIVP3, and TV1.21 (plotted in F–H and M–O) were ob-
tained from two or three independent experiments performed in
duplicate. The average values are plotted, and the data from the
replicate experiments can be found in Table S4C.
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Figure 3. Properties of the Autologous NAb Specificities
(A) Neutralization depletion assays with sera from one BG505 SOSIP.v5.2 recipient and all five BG505 SOSIP.v6-immunized animals using the autologous
BG505.T332N virus and a BG505 V3 peptide, as well as a set of different BG505 proteins. Neutralization of BG505.T332N from each individual sera was set at
100%, and the percent depletion was calculated when the V3 peptide or the different BG505 proteinswere added in the assay. The percentage shown is themean
of two different experiments.
(B) Neutralization assays with BG505.T332N PNGS mutants. The ID50 of the individual sera with the parental BG505.T332N virus was set at 100%, and the
percent reduction in ID50 when the respective PNGSs are introduced is shown. See also Table S4B.
(C) Neutralization of maternal MG505 viruses and heterologous TV1.21 mutant viruses. The ID50s are shown. Strong neutralization (ID50 > 1,000) is shown in red;
1,000 > ID50 > 100 is shown in orange; 100 > ID50 > 50 is shown in yellow, and no neutralization (ID50 < 50) is shown in white.experiments using a BG505 V3 peptide and a set of BG505
proteins: SOSIP.664 gp140, gp120, gp120-DV1V2, gp120-
DV3, and gp120-7C3 (Sanders et al., 2015). All proteins con-
tained the D368R substitution to prevent neutralization by
CD4 binding and interference in neutralization assays. The
gp120-7C3 contains seven substitutions in residues 354–363
in the C3 domain that were under selective pressure in the
BG505-infected infant (Goo et al., 2014; Sanders et al., 2015).
One BG505 SOSIP.v5.2 recipient animal was also included in
the analyses.
The autologous NAb response in all SOSIP.v6 recipients and
the one SOSIP.v5.2 recipient rabbit was completely depleted
when the sera were preincubated with BG505 SOSIP.664
D368R trimer, confirming that the neutralization was trimer
directed (Figure 3A). gp120, gp120-DV1V2, and gp120-DV3
were also efficient at depleting the BG505.T332N neutralization,
indicating that most of the autologous NAb response was
directed to gp120-associated epitope(s) that did not involve
V1V2 or V3. Rabbit 1831 was an exception. In this animal,
gp120-DV3 was considerably less efficient at depleting
BG505.T332N neutralization compared to full-length gp120,
suggesting that the V3 domain was involved in the (presentation
of) the epitope for the autologous NAb response in this
animal. The gp120-7C3 protein was unable to deplete the
BG505.T332N NAb activity from the sera of rabbit 1833 and
poorly effective in depleting the BG505.T332N NAb activity1814 Cell Reports 20, 1805–1817, August 22, 2017from animal 1831, suggesting that residues 354–363, in the C3
domain, are involved in the epitope(s) for the autologous NAb ac-
tivity in these animals. BG505.T332N neutralization of all sera
was unaffected by addition of the BG505 V3 peptide, confirming
that autologous NAb response was not directed against simple
linear epitopes in the V3 domain that are associated with tier-
1A virus neutralization (Figure 3A; Sanders et al., 2015).
Next, we tested neutralization of BG505.T332N mutants, spe-
cifically focusing on virus mutants in which holes in the BG505
trimer glycan shield that are immunogenic in rabbits were filled
in by restoring the respective predicted N-linked glycan sites
(PNGSs) (Klasse et al., 2016; McCoy et al., 2016). We previously
found that these holes, especially a large glycan hole centered
around positions 241 and 289, are frequent targets of autologous
BG505.T332N NAb responses induced by BG505 SOSIP trimers
(Klasse et al., 2016).
Introduction of PNGSs at positions 241 and 289 almost
completely abolished BG505.T332N neutralization by sera
from three out of five SOSIP.v6 recipients, as well as one
SOSIP.v5.2 recipient (animals 1819, 1829, 1830, and 1832),
showing that the NAb activity in these animals was dominated
by Ab specificities targeting the 241/289 hole (Figure 3B; Table
S4B). The NAb activity in four other rabbits tested, two receiving
SOSIP.v5.2 and two receiving SOSIP.v6 (animals 1831 and
1833), were much less affected by the PNGSs knockin muta-
tions, showing that the NAb response in those rabbits was only
partly directed to the 241/289 glycan hole. The introduction of
the PNGSs at position 130 generally had a much smaller effect
on the NAb sensitivity compared to the introduction of PNGSs
at positions 241 and 289. The largest effects were observed
for animals 1819 (SOSIP.v5.2) and 1832 (SOSIP.v6), in which
cases the NAb activity was reduced by 50%.
The finding that introduction of the PNGSs at 241 and 289 only
had a partial effect on the NAb activity in animals 1831 and 1833
is consistent with the observation that the gp120-7C3 protein did
not deplete the NAb activity from the sera of these two animals.
Thus, while the NAb specificities of three SOSIP.v6 recipient
animals appear to be directed to the 241/289 glycan hole, those
in the two other animals appear to be predominantly targeting an
epitope that is affected by residues 354–363.
We also tested the maternal virus clones MG505.A2 and
MG505.H3. While MG505.A2 has 14 amino-acid differences in
gp160 compared to BG505.T332N, only one involves a change
in a PNGSs: N332T. MG505.H3 contains 24 amino-acid differ-
ences compared to BG505.T332N, including the presence of
a PNGS at 241 and the lack of PNGSs at positions 190, 234,
332, 363, and 411.
The sera of three rabbits immunized with BG505 SOSIP.v6
neutralized MG505.A2, but none immunized with BG505
SOSIP.v5.2 did. While MG505.A2 has a hole at position 241,
the amino acid at that position is different compared to
BG505.T332N (K for MG505.A2 and S for BG505.T332N). To
mimic the BG505.T332N virus, a K241S substitution was intro-
duced into MG505.A2. The sera from all the rabbits, except
one animal, became substantially more sensitive to this virus,
suggesting that the NAb specificities in these sera were directed
toward this glycan hole, but were also dependent on the compo-
sition of amino acid 241. One exception was animal 1833, which
did not neutralize MG505.A2 or its K241S variant, in agreement
with the observation that the response in this animal did not
target the 241/289 hole. Furthermore, although the serum from
animal 1831 potently neutralized the MG505.A2 K241S virus,
it also neutralized the parental MG505.A2 virus effectively,
providing further evidence that NAb specificities other than those
directed to the 241/289 hole were present in this animal. Finally,
when sera were tested against the MG505.H3 virus, only two
rabbits (1830 and 1831, both recipients of BG505 SOSIP.v6)
neutralized this virus and then at low titer (Figure 3C), suggesting
that any or all of the 24 amino-acid changes in the MG505.H3
virus cause resistance to the NAb specificities present in the
SOSIP.v6-immunized rabbit sera.
Finally, to obtain information on the heterologous NAb re-
sponses, we tested some of the sera against a set of TV1.21
pseudovirus mutants. The results showed that knocking out
the N160 or N332 glycan enhanced TV1.21 neutralization
by SOSIP.v6 sera, suggesting that these glycans shield the het-
erologous neutralization epitope(s) targeted by the SOSIP.v6
recipient animals. Conversely, the K169E mutation ablated
neutralization, suggesting that K169 is part of the neutralization
epitope, or that the K169E mutation destroys the target epitope
by indirect means. Removal of the N276 glycan had no effect on
the sensitivity to the SOSIP.v6 sera (Figure 3C; Table S4C).
Because of the poor magnitude of the other heterologous NAb
titers, we were not able to map them.DISCUSSION
We describe the creation of native-like SOSIP trimers that are
stabilized by the introduction of additional disulfide bonds. The
most stable variant, BG505 SOSIP.v6, has its major Tm at
92.2C and a minor Tm at 78.8C, representing an increase of
24.5C and 11.1C over the prototypic SOSIP.664 design. The
most stable trimers contain two new disulfide bonds per
gp120-gp41 protomer, in addition to SOS. The 30 intra-molecu-
lar disulfide bonds naturally present in the trimer (ten per proto-
mer) are located within the inner or outer domains of gp120 or, in
one case, the immunodominant loop of gp41. In contrast, the en-
gineered bonds are all inter-domain.
The inter-subunit disulfide bond linking gp120 residue-501
to gp41 residue-605 (the ‘‘SOS bond’’) was positioned without
the availability of structural information on the gp120-gp41 inter-
face (Binley et al., 2000). The cryo-EM structure of the native,
membrane-associated trimer (Lee et al., 2016) confirms the ac-
curacy with which this bond was placed in the SOSIP trimer.
The newly introduced gp41 cysteine residues that successfully
form inter-subunit disulfide bonds are located between the a6
and a7 segments (i.e., HR1N) that were not well resolved in the
initial BG505 SOSIP.664 trimer structures (Julien et al., 2013a;
Lyumkis et al., 2013; Pancera et al., 2014). More recent struc-
tures and HD-X experiments imply that this region in the SOSIP
structuresmight be quite dynamic and, hence, capable of adopt-
ing multiple conformations (Garces et al., 2015; Guttman et al.,
2014). The finding that cysteine residues at multiple positions
in gp41 HR1 can pair with gp120 residues 72 or 73 is consistent
with the flexibility of this region (Lee et al., 2016). However, the
trimer structure predicted various other positions for cysteine
substitutions that did not, in practice, lead to the efficient forma-
tion of new disulfide bonds. One explanation is that the presence
of additional cysteine residues can sometimes interfere with the
proper oxidative folding and disulfide bond isomerization in the
endoplasmic reticulum, leading to the production of misfolded
proteins that are subsequently degraded (Bulleid and van Lith,
2014).
While a previous report showed a correlation between trimer
stability and the ability to induce autologous NAb responses
(Feng et al., 2016), we did not observe such a correlation
here. Thus, the BG505 SOSIP.664, SOSIP.v4.1, SOSIP.v5.1,
SOSIP.v5.2, and SOSIP.v6 trimers, displaying a wide range of
stabilities, were all equivalent in inducing BG505.T332N NAbs.
However, the observation that the BG505 SOSIP.v6 trimer and
the ZM197M SOSIP.v5 trimer were more efficient at inducing
heterologous tier-2 NAb responses suggests that the relation-
ship between trimer stability and the ability to induce NAbs is
likely to be complex. Regardless, the BG505 SOSIP.v6 and
ZM197M SOSIP.v5.2 trimers have encouraging immunogenicity
properties in rabbits and constitute a baseline for further trimer
design and delivery improvements. An additional virtue of a
more stable vaccine immunogen is an increased shelf life and
simplified storage capacity under real-word conditions (Karp
et al., 2015).
From a broader perspective, the reduced conformational flex-
ibility of stabilized trimers may help maintain them in the ground
state for longer in vivo, thereby maximizing the presentation ofCell Reports 20, 1805–1817, August 22, 2017 1815
bNAb epitopes and increasing the probability of a successful
encounter with susceptible but rare B cells. How these various
factors intersect to drive the induction of higher titer autologous
and heterologous tier-2 NAb titers is likely to be also influenced
by the genotype of the trimer, as well as its design.
EXPERIMENTAL PROCEDURES
Trimer Expression and Purification
The constructs expressing BG505, B41, AMC008, and ZM1097M SOSIP.664
were transiently expressed in adherent 293T cells or suspension 293F cells in
the presence of furin and purified using PGT145-affinity chromatography, as
previously described (Julien et al., 2013a, 2015; Pugach et al., 2015; Sanders
et al., 2013; de Taeye et al., 2015).
Antigenicity Assays
SPR analyses were performed with His-tagged trimers immobilized to CM5
chips, as previously described (Derking et al., 2015; Yasmeen et al., 2014).
D7324-capture, nickel nitrilotriacetic acid (Ni-NTA)-capture, and thermosta-
bility ELISAs have been described elsewhere (Derking et al., 2015; Sanders
et al., 2013; de Taeye et al., 2015).
Biophysical Techniques
Multiple biophysical techniques were used to analyze the properties of the Env
trimers, including DLS, SAXS, differential scanning calorimetry (DSC), hydro-
philic interaction chromatography-ultra-performance liquid chromatography
(HILIC-UPLC), and HDX-MS. Images of Env trimers were generated by nega-
tive stain EM (NS-EM) following previously described procedures (Sanders
et al., 2013). X-ray crystallography was performed with BG505 Env trimer
together with different Fabs as previously described (Julien et al., 2013a).
Neutralization Assays
We used Env-pseudotyped or chimeric molecular clone viruses to perform
neutralization assays at Duke University Medical Center, Academic Medical
Center, and Weill Medical College of Cornell University (Sanders et al., 2013;
Klasse et al., 2016).
Statistics
Different groups in rabbit immunizations were compared by two-tailed Mann-
Whitney U tests. Kruskal-Wallis with Dunn’s post-test was used when differ-
ences between the entire heterologous tier-2 panel were addressed.
Rabbit Immunizations
Rabbits were immunized with 22 mg of trimer and ISCOMATRIX at weeks 0, 4,
and 20. Rabbit immunizations were performed under contract at Covance
Research Products Inc. (Denver, PA, USA) under permits with approval
numbers C0022-15, C0119-15, and C0120-15.
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